NuCana (NASDAQ:NCNA) Shares Down 2.9% – What’s Next?

Shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) were down 2.9% during mid-day trading on Thursday. The company traded as low as $0.97 and last traded at $1.02. 55,147 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 253,137 shares. The stock had previously closed at $1.05.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of NuCana in a research note on Thursday. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

NuCana Stock Down 2.9%

The stock has a market capitalization of $4.12 million, a price-to-earnings ratio of -0.26 and a beta of 2.30. The company’s fifty day simple moving average is $1.33 and its 200 day simple moving average is $1.62.

NuCana (NASDAQ:NCNA) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($2.65) by $1.66.

NuCana Company Profile

NuCana plc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company applies its ProTide technology platform to existing nucleoside analogues, with the goal of improving their delivery into tumor cells, increasing anticancer activity and overcoming mechanisms of drug resistance.

NuCana’s pipeline has included Acelarin (NUC-1031), a ProTide-based version of gemcitabine investigated in several solid tumors, including pancreatic, biliary tract and ovarian cancers.